France Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation. In this conversation, Dominique Bery explains how France is shaping Ipsen’s next phase of growth, from oncology leadership to deeper…
France Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in late-stage clinical development across neuroscience and oncology. In this conversation, Franck Cousserans, General Manager France and Benelux, reflects on how…
Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…
USA Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s Life Sciences Industry Cluster Strategy and Action Plan, which aims to create 10,000 new industry jobs by 2030 and explains…
USA Lonza’s transformation under the One Lonza Strategy comes at a moment of significant change for the global biologics and CDMO sectors. Gordon Bates, Head of Integrated Biologics, reflects on the rationale behind the company’s new organisational model, and how a more unified structure is designed to accelerate decision-making and strengthen…
France Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on the scientific foundations of RNAi, the strengths and pressures of the French rare-disease ecosystem, and the conditions needed to ensure…
France Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a new phase of growth at the intersection of innovation, sovereignty and international ambition. In this conversation, recently appointed CEO Sébastien…
Taiwan Yenchen Huang, Head of Investment, VP at Diamond Biofund, one of Taiwan’s pioneering evergreen venture capital funds focused on life sciences, our interviewee brings a unique perspective combining scientific training with financial expertise. Since joining the fund in 2014, shortly after its 2013 establishment, Huang has helped guide early-stage biotechnology…
France ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the agency’s digital transformation, the pressure to accelerate clinical research, the importance of early access, and the work underway to strengthen…
Taiwan Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep understanding of cross-cultural business dynamics and healthcare system transformation. Since assuming his current role, he has spearheaded an ambitious organisational…
USA Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the launch of a new 2030 strategy and revised mission aimed at integrating HEOR into everyday health policy decision-making. This includes…
MEA Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward Saudi biotechs, Egypt’s collaboration with Turkey on pharma manufacturing, and China’s ‘health silk road’ in Africa. Saudi Arabia pitches…
See our Cookie Privacy Policy Here